128 related articles for article (PubMed ID: 38072195)
1. Recapitulating primary immunodeficiencies with expanded potential stem cells: Proof of concept with STAT1 gain of function.
Liu X; Chan VSF; Smith KGC; Ming C; Or CS; Tsui FTW; Gao B; Cook MC; Liu P; Lau CS; Li PH
J Allergy Clin Immunol; 2024 Apr; 153(4):1125-1139. PubMed ID: 38072195
[TBL] [Abstract][Full Text] [Related]
2. Ruxolitinib partially reverses functional natural killer cell deficiency in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations.
Vargas-Hernández A; Mace EM; Zimmerman O; Zerbe CS; Freeman AF; Rosenzweig S; Leiding JW; Torgerson T; Altman MC; Schussler E; Cunningham-Rundles C; Chinn IK; Carisey AF; Hanson IC; Rider NL; Holland SM; Orange JS; Forbes LR
J Allergy Clin Immunol; 2018 Jun; 141(6):2142-2155.e5. PubMed ID: 29111217
[TBL] [Abstract][Full Text] [Related]
3. Impact of JAK Inhibitors in Pediatric Patients with STAT1 Gain of Function (GOF) Mutations-10 Children and Review of the Literature.
Deyà-Martínez A; Rivière JG; Roxo-Junior P; Ramakers J; Bloomfield M; Guisado Hernandez P; Blanco Lobo P; Abu Jamra SR; Esteve-Sole A; Kanderova V; García-García A; Lopez-Corbeto M; Martinez Pomar N; Martín-Nalda A; Alsina L; Neth O; Olbrich P
J Clin Immunol; 2022 Jul; 42(5):1071-1082. PubMed ID: 35486339
[TBL] [Abstract][Full Text] [Related]
4. JAK inhibitor treatment for inborn errors of JAK/STAT signaling: An ESID/EBMT-IEWP retrospective study.
Fischer M; Olbrich P; Hadjadj J; Aumann V; Bakhtiar S; Barlogis V; von Bismarck P; Bloomfield M; Booth C; Buddingh EP; Cagdas D; Castelle M; Chan AY; Chandrakasan S; Chetty K; Cougoul P; Crickx E; Dara J; Deyà-Martínez A; Farmand S; Formankova R; Gennery AR; Gonzalez-Granado LI; Hagin D; Hanitsch LG; Hanzlikovà J; Hauck F; Ivorra-Cortés J; Kisand K; Kiykim A; Körholz J; Leahy TR; van Montfrans J; Nademi Z; Nelken B; Parikh S; Plado S; Ramakers J; Redlich A; Rieux-Laucat F; Rivière JG; Rodina Y; Júnior PR; Salou S; Schuetz C; Shcherbina A; Slatter MA; Touzot F; Unal E; Lankester AC; Burns S; Seppänen MRJ; Neth O; Albert MH; Ehl S; Neven B; Speckmann C
J Allergy Clin Immunol; 2024 Jan; 153(1):275-286.e18. PubMed ID: 37935260
[TBL] [Abstract][Full Text] [Related]
5. Ex vivo effect of JAK inhibition on JAK-STAT1 pathway hyperactivation in patients with dominant-negative STAT3 mutations.
Lobo PB; Guisado-Hernández P; Villaoslada I; de Felipe B; Carreras C; Rodriguez H; Carazo-Gallego B; Méndez-Echevarria A; Lucena JM; Aljaro PO; Castro MJ; Noguera-Uclés JF; Milner JD; McCann K; Zimmerman O; Freeman AF; Lionakis MS; Holland SM; Neth O; Olbrich P
J Clin Immunol; 2022 Aug; 42(6):1193-1204. PubMed ID: 35507130
[TBL] [Abstract][Full Text] [Related]
6. Severe Early-Onset Combined Immunodeficiency due to Heterozygous Gain-of-Function Mutations in STAT1.
Baris S; Alroqi F; Kiykim A; Karakoc-Aydiner E; Ogulur I; Ozen A; Charbonnier LM; Bakır M; Boztug K; Chatila TA; Barlan IB
J Clin Immunol; 2016 Oct; 36(7):641-8. PubMed ID: 27379765
[TBL] [Abstract][Full Text] [Related]
7. Utility of Ruxolitinib in a Child with Chronic Mucocutaneous Candidiasis Caused by a Novel STAT1 Gain-of-Function Mutation.
Bloomfield M; Kanderová V; Paračková Z; Vrabcová P; Svatoň M; Froňková E; Fejtková M; Zachová R; Rataj M; Zentsová I; Milota T; Klocperk A; Kalina T; Šedivá A
J Clin Immunol; 2018 Jul; 38(5):589-601. PubMed ID: 29934865
[TBL] [Abstract][Full Text] [Related]
8.
Zimmerman O; Olbrich P; Freeman AF; Rosen LB; Uzel G; Zerbe CS; Rosenzweig SD; Kuehn HS; Holmes KL; Stephany D; Ding L; Sampaio EP; Hsu AP; Holland SM
Front Immunol; 2019; 10():1433. PubMed ID: 31354696
[TBL] [Abstract][Full Text] [Related]
9. Neutrophils in STAT1 Gain-Of-Function Have a Pro-inflammatory Signature Which Is Not Rescued by JAK Inhibition.
Parackova Z; Vrabcova P; Zentsova I; Sediva A; Bloomfield M
J Clin Immunol; 2023 Oct; 43(7):1640-1659. PubMed ID: 37358695
[TBL] [Abstract][Full Text] [Related]
10. Stepwise Reversal of Immune Dysregulation Due to STAT1 Gain-of-Function Mutation Following Ruxolitinib Bridge Therapy and Transplantation.
Kayaoglu B; Kasap N; Yilmaz NS; Charbonnier LM; Geckin B; Akcay A; Eltan SB; Ozturk G; Ozen A; Karakoc-Aydiner E; Chatila TA; Gursel M; Baris S
J Clin Immunol; 2021 May; 41(4):769-779. PubMed ID: 33475942
[TBL] [Abstract][Full Text] [Related]
11. Molecular and Phenotypic Characterization of Nine Patients with STAT1 GOF Mutations in China.
Chen X; Xu Q; Li X; Wang L; Yang L; Chen Z; Zeng T; Xue X; Xu T; Wang Y; Jia Y; Zhao Q; Wu J; Liang F; Tang X; Yang J; An Y; Zhao X
J Clin Immunol; 2020 Jan; 40(1):82-95. PubMed ID: 31686315
[TBL] [Abstract][Full Text] [Related]
12. Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation.
Weinacht KG; Charbonnier LM; Alroqi F; Plant A; Qiao Q; Wu H; Ma C; Torgerson TR; Rosenzweig SD; Fleisher TA; Notarangelo LD; Hanson IC; Forbes LR; Chatila TA
J Allergy Clin Immunol; 2017 May; 139(5):1629-1640.e2. PubMed ID: 28139313
[TBL] [Abstract][Full Text] [Related]
13. Case report: Myocarditis in congenital STAT1 gain-of function.
Staels F; Roosens W; Giovannozzi S; Moens L; Bogaert J; Iglesias-Herrero C; Gijsbers R; Bossuyt X; Frans G; Liston A; Humblet-Baron S; Meyts I; Van Aelst L; Schrijvers R
Front Immunol; 2023; 14():1095595. PubMed ID: 37020552
[TBL] [Abstract][Full Text] [Related]
14. Case report: A STAT1 gain-of-function mutation causes a syndrome of combined immunodeficiency, autoimmunity and pure red cell aplasia.
Xie Y; Shao F; Lei J; Huang N; Fan Z; Yu H
Front Immunol; 2022; 13():928213. PubMed ID: 36105803
[TBL] [Abstract][Full Text] [Related]
15. Clinical Relevance of Gain- and Loss-of-Function Germline Mutations in STAT1: A Systematic Review.
Zhang W; Chen X; Gao G; Xing S; Zhou L; Tang X; Zhao X; An Y
Front Immunol; 2021; 12():654406. PubMed ID: 33777053
[No Abstract] [Full Text] [Related]
16. STAT1 gain-of-function heterozygous cell models reveal diverse interferon-signature gene transcriptional responses.
Scott O; Lindsay K; Erwood S; Mollica A; Roifman CM; Cohn RD; Ivakine EA
NPJ Genom Med; 2021 May; 6(1):34. PubMed ID: 33990617
[TBL] [Abstract][Full Text] [Related]
17. Dysregulated IFN-γ signals promote autoimmunity in STAT1 gain-of-function syndrome.
Largent AD; Lambert K; Chiang K; Shumlak N; Liggitt D; Oukka M; Torgerson TR; Buckner JH; Allenspach EJ; Rawlings DJ; Jackson SW
Sci Transl Med; 2023 Jul; 15(703):eade7028. PubMed ID: 37406138
[TBL] [Abstract][Full Text] [Related]
18. Ruxolitinib treatment of a patient with steroid-dependent severe autoimmunity due to STAT1 gain-of-function mutation.
Moriya K; Suzuki T; Uchida N; Nakano T; Katayama S; Irie M; Rikiishi T; Niizuma H; Okada S; Imai K; Sasahara Y; Kure S
Int J Hematol; 2020 Aug; 112(2):258-262. PubMed ID: 32180118
[TBL] [Abstract][Full Text] [Related]
19. Signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations and disseminated coccidioidomycosis and histoplasmosis.
Sampaio EP; Hsu AP; Pechacek J; Bax HI; Dias DL; Paulson ML; Chandrasekaran P; Rosen LB; Carvalho DS; Ding L; Vinh DC; Browne SK; Datta S; Milner JD; Kuhns DB; Long Priel DA; Sadat MA; Shiloh M; De Marco B; Alvares M; Gillman JW; Ramarathnam V; de la Morena M; Bezrodnik L; Moreira I; Uzel G; Johnson D; Spalding C; Zerbe CS; Wiley H; Greenberg DE; Hoover SE; Rosenzweig SD; Galgiani JN; Holland SM
J Allergy Clin Immunol; 2013 Jun; 131(6):1624-34. PubMed ID: 23541320
[TBL] [Abstract][Full Text] [Related]
20. Signal transducer and activator of transcription gain-of-function primary immunodeficiency/immunodysregulation disorders.
Consonni F; Dotta L; Todaro F; Vairo D; Badolato R
Curr Opin Pediatr; 2017 Dec; 29(6):711-717. PubMed ID: 28914637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
